![7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)]()
7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)Chi, K.N.; Hotte, S.J.; Yu, E.; Tu, D.; Eigl, B.; Tannock, I.; Saad, F.; North, S.; Powers, J.; Eisenhauer, E. · European Journal of Cancer Supplements · 2009